Please assess the completion status of the following clinical trial:

Trial Title: Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~3.1.1 IgM paraprotein identified on serum immunofixation electrophoresis OR light chain-restricted CD20+ lymphoplasmacytic population on biopsy of bone marrow or lymph node (identified by H\&E/immunohistochemistry or flow cytometry) OR positive myeloid differentiation primary response gene 88 (MYD88-L265P) OR CXCR4WHIM mutation (CXCR4 mutation - warts, hypogammaglobulinemia, infections, myelokathexis) on submitted samples~3.1.2 Biopsy-proven relapsed or refractory AL amyloidosis~3.1.3 Age ≥ 18 years~3.1.4 Eastern Cooperative Oncology Group (ECOG) performance status \<2 (see Appendix A.)~3.1.5 Difference between serum free light chains (FLC) of \>30 mg/L or quantifiable IgM paraprotein \>0.5 g/L~3.1.6 Participants must have normal organ and marrow function as defined below:~* Absolute neutrophil count \> 1,000/mm3~* Platelets \> 50,000/mm3~3.1.7 Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~3.2.1 Previous treatment with idelalisib~3.2.2 Glomerular filtration rate (GFR) \<15 ml/min~3.2.3 Cardiac biomarker Stage III disease as determined by B-type natriuretic peptide (BNP) \>100 pg/mL and Troponin-I \>0.1 ng/mL (Girnius 2014)~3.2.4 alanine-aminotransferase (ALT)/aspartate aminotransferase (AST) values \>2.5x upper limit of normal, Bilirubin \>1.5 upper limit of normal (ULN)~3.2.5 Central nervous system (CNS) malignancy or other active malignancy~3.2.6 Lactating or pregnant women~3.2.7 Exposure to another investigational drug within 4 weeks prior to start of study treatment~3.2.8 Ongoing alcohol or drug addiction as determined by investigator~3.2.9 Amyloid-directed therapy within the past 28 days~3.2.10 History of Human Immunodeficiency Virus (HIV), active Hepatitis B Virus (HBV) (assessed by positive Hepatitis B polymerase chain reaction assay (PCR) or Hepatitis B Surface Antigen), and/or Hepatitis C Virus (HCV) infection~3.2.11 t(11,14) translocation identified on bone marrow cytogenetics or by Fluorescence in situ hybridization (FISH)~3.2.12 Known lytic bone lesions~3.2.13 Positive cytomegaly virus (CMV) Polymerase chain reaction (PCR)~3.2.14 Previously untreated AL amyloidosis (Newly diagnosed)~3.2.15 Unwilling or unable to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idelalisib (Type: EXPERIMENTAL): Idelalisib 100 mg twice daily with possible escalation after 3 months to 150 mg twice daily at investigator discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).